Contact:           Dacia Morris
                        (212) 543-5421
 

FOR IMMEDIATE RELEASE

RESEARCH STUDY OF ADOLESCENT SCHIZOPHRENIA UNDERWAY
AT THE NEW YORK STATE PSYCHIATRIC INSTITUTE

Adolescents with Schizophrenia

May Be Eligible to Enroll

The New York State Psychiatric Institute (NYSPI) is one of the clinical trial sites in a nationwide research study evaluating the safety and effectiveness of an atypical antipsychotic medication in adolescents.

“Atypical anti-psychotic medications have demonstrated effectiveness and are now widely prescribed for adults, but there has been little research examining the use of these medications in a pediatric population,” said Bruce Waslick, M.D., who is the Principal Investigator for this research study at NYSPI.  “This trial will provide important data for clinicians when examining treatment options for adolescents with schizophrenia.”

The eight-week study is open to males and females between 13 and 17 years of age who meet the study’s eligibility requirements.  All pediatric patients enrolled will receive the study medication; two different dosing regimens will be evaluated.  Participants must be inpatients at the time of enrollment and may be eligible to enroll in an open-label extension trial lasting up to 12 months.  The permission and support of a parent or legal guardian, and assent of the child, is required throughout the study.  The same responsible adult must be available during clinic visits.

For more information about the study or how to refer a patient, please contact Aphrodite Kakouros at (212) 543-0266 during the hours between 9:00 am and 5:00 pm.

*To schedule an interview with Dr. Waslick, contact the Office of Public Information at (212) 543-5421.

 

Go Back to News Releases